Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Photo: Blake Nissen for The Boston Globe via Getty Images

Moderna has not been living up to contractual obligations to disclose the percentage of taxpayer dollars that are funding its coronavirus vaccine project, but the pharmaceutical company tells Axios that federal money makes up "100% funding of the program."

Why it matters: Moderna has received almost $1 billion in taxpayer grants to get its vaccine through clinical trials and is considering setting the highest price of all coronavirus vaccine candidates.

Driving the news: Moderna's contract with the Biomedical Advanced Research and Development Authority, which is part of Health and Human Services, includes a provision that requires Moderna to "clearly state ... the percentage of the total costs of the program" financed with federal vs. private dollars.

  • Moderna has not done this in any of its press releases tied to its coronavirus vaccine.
  • Two consumer advocacy groups, Public Citizen and Knowledge Ecology International, are now pushing HHS to "enforce the provision in this contract and all other applicable contracts."

Between the lines: This provision is commonly called the Stevens Amendment, and it turns out the federal government has done a poor job of enforcing it, according to a Government Accountability Office report from last year.

What they're saying: HHS did not say if it issued Moderna an exemption from this provision, only saying in a response:

  • "Moderna provides the required acknowledgement to the federal government for funding and other support provided to develop the vaccine. The company would need to identify for you what percentage of this specific contract is federally funded. We continue to collaborate with companies as they put out press releases to ensure accurate information."

Moderna said in multiple responses that it "request[s] BARDA review for each of our press releases or other disclosures before we issue ... and are comfortable that the information included in our public disclosures is consistent with BARDA's expectations."

  • Moderna said the language in its original BARDA funding press release — "BARDA will fund the advancement of mRNA-1273 to FDA licensure" — "made clear the extent of BARDA's 100% funding of the program."

Go deeper

Dave Lawler, author of World
Nov 12, 2020 - World

As countries line up for Russia's vaccine, not everyone is buying it

"Trust me. It's safe." Photo: Alexy Nikolsky/Sputnik/AFP via Getty

Not to be outdone by Pfizer’s big announcement, Russia’s state-run Gamaleya Research Institute announced Wednesday that its Sputnik V vaccine is 92% effective.

Why it matters: Experts have criticized the lack of transparency around the vaccine and the haste with which the Kremlin approved it, but several countries are lining up to gain access.

Nov 12, 2020 - Health

The trickiest vaccine launch in U.S. history

Illustration: Sarah Grillo/Axios

Even if the federal government manages to secure the cash needed for COVID-19 vaccine distribution — and that's a big if — there's still a huge task ahead at the state level.

Why it matters: America has never attempted to vaccinate so many people on such short notice, with so many lives on the line.

Updated 18 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Sarah Grillo/Axios

  1. Health: Most COVID-19 survivors can weather risk of reinfection, study says — "Twindemic" averted as flu reports plummet amid coronavirus crisis
  2. Vaccine: Pfizer begins study on 3rd vaccine dose as booster shot against new strains — Republicans are least likely to want the coronavirus vaccine
  3. U.S. news: California surpasses 50,000 deaths COVID-19 deaths, more than any other state — Jimmy and Rosalynn Carter return to church after receiving COVID-19 vaccines
  4. Local: Public transit ridership in Twin Cities dropped 53% amid pandemic — Data firm predicts "complete chaos" in next phases of Florida's vaccine rolloutAlaska Gov. Mike Dunleavy tests positive for the coronavirus